Product Description
Sym021 is a monoclonal antibody that binds PD1 and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD1-mediated inhibition of the immune response. (Sourced from: https://www.symphogen.com/pipeline/products/sym021/)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Symphogen A/S
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, France, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Adenocarcinoma|Biliary Tract Cancer|Bladder Cancer|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Sym024-01 | P1 |
Completed |
Esophageal Cancer|Pancreatic Ductal Carcinoma|Mesothelioma|Head and Neck Cancer|Cervical Cancer|Pancreatic Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Colorectal Cancer|Adenocarcinoma|Cholangiocarcinoma |
2024-11-22 |
|
| Sym021-02 | P1 |
Completed |
Biliary Tract Cancer|Cholangiocarcinoma|Squamous Cell Carcinoma|Bladder Cancer|Esophageal Cancer |
2024-06-03 |